Menu
← Oncology Approval Tracker
FDA DECISION ·
Imjudo + Imfinzi
tremelimumab-actl plus durvalumab · AstraZeneca
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with unresectable hepatocellular carcinoma receiving tremelimumab with durvalumab.
LAMPGEN ANALYSIS
Why it matters
This introduces a CTLA-4 and PD-L1 combination for unresectable liver cancer.
What research teams should watch
Distinguish baseline liver disease from possible immune-mediated hepatic toxicity and track the two agents separately.
PRIMARY RECORDS